These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19877761)

  • 1. JAK2 V617F mutation detection: laboratory comparison of two kits using RFLP and qPCR.
    Shammaa D; Bazarbachi A; Halas H; Greige L; Mahfouz R
    Genet Test Mol Biomarkers; 2010 Feb; 14(1):13-5. PubMed ID: 19877761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Usefulness of real-time semi-quantitative PCR, JAK2 MutaScreen kit for JAK2 V617F screening].
    Chae H; Lee JH; Lim J; Jung SW; Kim M; Kim Y; Han K; Cho BS; Cho SG; Lee JW; Min WS
    Korean J Lab Med; 2009 Jun; 29(3):243-8. PubMed ID: 19571623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitive and accurate quantification of JAK2 V617F mutation in chronic myeloproliferative neoplasms by droplet digital PCR.
    Waterhouse M; Follo M; Pfeifer D; von Bubnoff N; Duyster J; Bertz H; Finke J
    Ann Hematol; 2016 Apr; 95(5):739-44. PubMed ID: 26931113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J; Fijnheer R; Walsh IB; Hermans MH
    Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
    Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
    Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 V617F "indeterminate" results by MutaScreen can be easily resolved using MutaQuant kits.
    Hoteit RM; Shammaa DM; Mahfouz RA
    Genet Test Mol Biomarkers; 2012 Feb; 16(2):146-9. PubMed ID: 21933004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2 V617F gene mutation in the laboratory work-up of myeloproliferative disorders: experience of a major referral center in Lebanon.
    Mahfouz RA; Hoteit R; Salem Z; Bazarbachi A; Mugharbel A; Farhat F; Ziyadeh A; Ibrahim A; Taher A
    Genet Test Mol Biomarkers; 2011 Apr; 15(4):263-5. PubMed ID: 21198321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accurate quantitation of JAK2 V617F allele burden by array-based digital PCR.
    Kinz E; Leiherer A; Lang AH; Drexel H; Muendlein A
    Int J Lab Hematol; 2015 Apr; 37(2):217-24. PubMed ID: 24963593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BsaXI/RFLP analysis of initial or selectively reamplified PCR product is unreliable in detecting the V617F mutation in JAK2.
    Shepard GC; Lawson HL; Hawkins GA; Owen J
    Int J Lab Hematol; 2011 Jun; 33(3):267-71. PubMed ID: 21118387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods.
    Lucia E; Martino B; Mammi C; Vigna E; Mazzone C; Gentile M; Qualtieri G; Bisconte MG; Naccarato M; Gentile C; Laganà C; Romeo F; Neri A; Nobile F; Morabito F
    Leuk Lymphoma; 2008 Oct; 49(10):1907-15. PubMed ID: 18720212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.
    Rapado I; Albizua E; Ayala R; Hernández JA; Garcia-Alonso L; Grande S; Gallardo M; Gilsanz F; Martinez-Lopez J
    Ann Hematol; 2008 Sep; 87(9):741-9. PubMed ID: 18575865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
    da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].
    Zhang SJ; Li WD; Song JH; Xu W; Qiu HX; Li JY
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2109-12. PubMed ID: 17988529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms.
    Fontanelli G; Baratè C; Ciabatti E; Guerrini F; Grassi S; Del Re M; Morganti R; Petrini I; Arici R; Barsotti S; Metelli MR; Danesi R; Galimberti S
    Int J Lab Hematol; 2015 Dec; 37(6):766-73. PubMed ID: 26189968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation.
    Tan AY; Westerman DA; Dobrovic A
    Am J Clin Pathol; 2007 Jun; 127(6):977-81. PubMed ID: 17509995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methods for the detection of the JAK2 V617F mutation in human myeloproliferative disorders.
    Campbell PJ; Scott LM; Baxter EJ; Bench AJ; Green AR; Erber WN
    Methods Mol Med; 2006; 125():253-64. PubMed ID: 16502590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of JAK2 V617F mutation in Indian patients with chronic myeloproliferative disorders.
    Sazawal S; Bajaj J; Chikkara S; Jain S; Bhargava R; Mahapatra M; Saxena R
    Indian J Med Res; 2010 Oct; 132():423-7. PubMed ID: 20966521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.